Skip to main content

Table 3 Efficacy of a single oral dose of Simparica Trio™ against natural Toxocara canis infections in dogs presented as veterinary patients in the USA

From: Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA

SampleaTreatment groupbnEgg count per gram fecesEfficacy
Geometric mean95% CI% ReductionTest statisticc
Pre-treatmentSimparica Trio™83272.98156.11–476.79
Iver+Pyr31137.6562.90–299.85
Post-treatmentSimparica Trio™832.060.75–4.3399.2t(112)= 17.18, P < 0.0001
Iver+Pyr311.890.33–5.2798.6t(112)= 9.04, P < 0.0001
  1. aPre-treatment sample collected on Day-1 or Day 0 prior to treatment. Post-treatment sample collected between Day 8 and 14
  2. bSingle oral administration of Simparica Trio™ on Day 0 to provide dose ranges of 1.2–2.4 mg/kg sarolaner, 24–48 µg/kg moxidectin and 5–10 mg/kg pyrantel (as pamoate salt)
  3. cTest statistic and P-value for difference (pre-treatment – post-treatment) within group
  4. Abbreviations: Iver, ivermectin; Pyr, pyrantel pamoate; CI, confidence interval